Viyash Scientific
VIYASHNSE

Viyash Scientific

₹204.781.04 (0.51%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
203.12
Today’s high
207.55
52 week low
141.63
52 week high
257.85
Open price
204.09
Previous close
203.74
Live volume
4,90,643
Lower circuit
163.00
Upper circuit
244.48

Fundamentals

Market Cap
₹8,919Cr
ROE
15.22%
P/E Ratio(TTM)
59.69
EPS(TTM)
3.42
P/B Ratio
10.54
Dividend Yield
0.00%
Industry P/E
33.38
Book Value
19.37
Debt to Equity
0.61
Face Value
2

Financial performance

Quarterly
Yearly
All Financials
DEC '25
Revenue (Cr)
₹872
+1.71%
Profit (Cr)
₹48.52
-33.44%
02505007501k
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Revenue growthValue
1Y (TTM)+12%
3Y CAGR+3%
Profit growthValue
1Y (TTM)+16%
3Y CAGR-10%

About

SeQuent Scientific Limited stands as India's foremost animal health player, demonstrating an expanding global presence with state-of-the-art manufacturing capabilities across multiple continents. Its core vision is to establish itself as a premier integrated animal health company dedicated to delivering high-quality veterinary solutions around the world. The company's mission focuses on competitively delivering quality products while upholding strict standards of quality, governance, and compliance in all its operations. It offers an integrated portfolio that includes Active Pharmaceutical Ingredients (APIs) and Finished Drug Formulations (FDFs) to meet the industry's evolving needs. Through its animal health brand Alivira, the company is focused on advancing veterinary care by offering solutions that promote the well-being of animals. The company maintains a vast global reach with product registrations across numerous dosage forms, serving customers in over 90 countries.;
CEO/MD
Mr. Rajaram Narayanan
Founded in
1985
NSE symbol
VIYASH

Shareholding Pattern

Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Promoters
61.31%
Retail And Others
27.76%
Mutual Funds
6.44%
Foreign Institutions
2.94%
Other Domestic Institutions
1.54%

Mutual Funds Invested (2)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
Natco PharmaNATCOPHARM
₹1,114.60
+18.85 (1.72%)
L
    H
    19,627.7612.622.27
    ₹1,353.60
    +30.70 (2.32%)
    L
      H
      18,325.7638.935.21
      ₹703.40
      +3.70 (0.53%)
      L
        H
        17,327.2029.123.41
        ₹931.40
        +4.80 (0.52%)
        L
          H
          14,763.1334.382.24
          Livesquawk
          Viyash Scientific's Q3 net profit fell to ₹384M from ₹446M YoY. Q3 revenue rose to ₹8.6B, up from ₹7.7B YoY.
          Livesquawk
          Sequent Scientific appoints Haribabu Bodepudi as MD and Group CEO. Ramakant Singani to become CFO effective January 1, 2026.
          2026
          5
          Feb
          Quarterly Result
          Release date
          2025
          14
          Nov
          Quarterly Result
          Release date
          8
          Aug
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks